- Compass Pathways (CMPS, Financial) completes dosing in Part A of Phase 3 COMP005 trial for treatment-resistant depression.
- Top-line 6-week primary endpoint results expected in late June.
- Study tests a single 25 mg dose of COMP360 psilocybin versus placebo.
Compass Pathways plc (Nasdaq: CMPS), a leading biotechnology company focused on mental health innovations, has successfully completed dosing all participants in Part A of the Phase 3 COMP005 trial. This trial evaluates the efficacy of COMP360 psilocybin as a treatment for individuals with treatment-resistant depression (TRD).
The trial involves administering a single dose of either 25 mg of COMP360 or a placebo to participants. Preliminary activities included a necessary washout from current antidepressant medications. This study marks a significant advancement in addressing unmet needs within the field of mental health treatments.
The company remains on schedule to release the top-line 6-week primary endpoint results in late June. Kabir Nath, CEO of Compass Pathways, expressed the company's commitment to scientific innovation and highlighted the potential of COMP360 to offer new hope to patients who have not benefited from existing therapies.
The Phase 3 COMP005 trial is notable for being the largest multi-center study of its kind to complete recruitment, involving 258 participants across 32 sites in the United States. Compass Pathways continues to demonstrate its dedication to developing cutting-edge treatment options, potentially changing the standard of care for those afflicted by TRD.
